Clinical trial · Interventional
68Ga-FAPI PET/CT in Pancreatic Ductal Carcinoma
A Prospective Pilot Study to Explore Performance and Efficacy of 68Ga-FAPI PET/CT in Pancreatic Ductal Carcinoma Patients
NCT05275985CI-TRIAL-00057045unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Fibroblast activation protein (FAP) is overexpressed in cancer-associated fibroblasts (CAFs), which constitutes a major proportion of cells within the tumor microenvironment, especially in primary pancreatic ductal carcinoma (PDAC). In this prospective study, we aimed to evaluate the performance and value of 68Ga-FAPI-04 PET/CT in the patients with PDAC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| PDAC | Pancreatic Ductal Adenocarcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-FAPI Positron Emission Tomography-Computed Tomography | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 68Ga-FAPI PET/CT examination
- description
- Patients with suspected pancreatic lesions underwent 68Ga-FAPI PET/CT to distinguish benign and malignant lesions, to evaluate the resectability of lesions and to detect distant metastasis. The clinicians decided the treatment methods based on the results of 68Ga-FAPI PET/CT.
- interventionNames
- Diagnostic Test: 68Ga-FAPI Positron Emission Tomography-Computed Tomography
Primary outcomes (5)
- measure
- Standard Uptake Value (SUV）
- timeFrame
- through study completion, an average of 0.5 year
- description
- Determined and compared the SUV for detected lesions in 68Ga-FAPI
- measure
- The numbers of patients who been changed the treatment methods
- timeFrame
- through study completion, an average of 0.5 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with suspected pancreatic lesions 2. Signed written consent. Exclusion Criteria: 1. pregnancy; 2. breastfeeding; 3. any medical condition that in the opinion of the investigator may significantly interfere with study compliance
References
Publications (0)
Data not yet available
No reference posted for this study.